Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sprint Bioscience AB's enterprise value is kr273.6 Mil.
Sprint Bioscience AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr91.1 Mil. Therefore, Sprint Bioscience AB's EV-to-EBITDA for today is 3.00.
The historical rank and industry rank for Sprint Bioscience AB's EV-to-EBITDA or its related term are showing as below:
OSTO:SPRINT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2762.88 Med: -2.62 Max: 210.12
Current: 3
During the past 13 years, the highest EV-to-EBITDA of Sprint Bioscience AB was 210.12. The lowest was -2762.88. And the median was -2.62.
OSTO:SPRINT's EV-to-EBITDA is ranked better than 67.95% of 415
companies
in the Biotechnology industry
Industry Median: 11.92
vs OSTO:SPRINT: 3.00
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Sprint Bioscience AB (OSTO:SPRINT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sprint Bioscience AB's PE Ratio (TTM) for today is calculated as:
Sprint Bioscience AB's share price for today is kr3.62.
Sprint Bioscience AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Sprint Bioscience AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPRINT vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's EV-to-EBITDA falls into.
Sprint Bioscience AB's current Enterprise Value is kr273.6 Mil.
Sprint Bioscience AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr91.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB (OSTO:SPRINT) has a EV-to-EBITDA of 3.00 as of Aug. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sprint Bioscience AB. According to the industry distribution chart, Sprint Bioscience AB ranks #133 out of 415 companies in the Biotechnology industry, placing it in the top 32%.
Is Sprint Bioscience AB's EV-to-EBITDA too high?
Sprint Bioscience AB's current EV-to-EBITDA is 3.00. The Biotechnology industry median EV-to-EBITDA is 11.92. Sprint Bioscience AB's value of 3.00 is 74.8% below this industry median. Based on the distribution chart, Sprint Bioscience AB ranks #133 out of 415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #133 out of 415 companies for EV-to-EBITDA. This puts Sprint Bioscience AB in the upper half of its industry. The industry median EV-to-EBITDA is 11.92. Sprint Bioscience AB's value of 3.00 is 74.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.92, based on 415 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sprint Bioscience AB's current EV-to-EBITDA of 3.00 is 74.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Sprint Bioscience AB. For the Biotechnology industry, the median EV-to-EBITDA is 11.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current EV-to-EBITDA is 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Sprint Bioscience AB (OSTO:SPRINT) has a current EV-to-EBITDA of 3.00. The current EV-to-EBITDA is 3.00 and 74.8% below the Biotechnology industry median of 11.92. Sprint Bioscience AB's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current EV-to-EBITDA is 3.00 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
22GF Score
Get the complete analysis for OSTO:SPRINT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
